1.Negative article written in Forbes: http://www.forbes.com/sites/abrambrown/2013/09/04/how-is-a-329m-syringe-company-still-unprofitable-after-11-years/?partner=yahoomag
That article was written in April...
UNS Price at posting:
62.0¢ Sentiment: LT Sell Disclosure: Not Held